About Us
We’ve made significant contributions to the laboratory space for more than 80 years. Our work has helped define the science of in vitro diagnostics.
We’ve made significant contributions to the laboratory space for more than 80 years. Our work has helped define the science of in vitro diagnostics.
QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
Ortho began trading on the Nasdaq Global Select Market on January 28, 2021, under the symbol OCDX.
Ortho launched the first high-volume antibody and antigen tests authorized by the U.S. Food and Drug Administration (FDA). These COVID-19 solutions for mass-scale testing include two COVID-19 antibody tests – Total and IgG – both of which have FDA emergency use authorization and CE Marks, and an antigen test. See our COVID-19 innovation timeline [Download infographic]
Multi-test technology allows labs to run two frequently ordered tests simultaneously on one slide.
Ortho receives the CE Mark approval for its Immunodiagnostic HIV Combo Test, making it commercially available in countries that accept the CE Mark.
Ortho Clinical Diagnostics receives 510(k) clearance making it commercially available in the U.S. The ORTHO VISION Analyzer automates the full range of immunohematology testing and helps improve the safety of blood transfusions by reducing the lab’s reliance on manual methods.
Revolutionizing the field of diagnostics by providing clinical professionals with the means to receive high-quality results quickly, cleanly and economically.
Dr. Levine continues his breakthrough research into the mechanics of the Rh system in human blood. His research leads to the development of Rh immune globulin to protect Rh-negative women against isoimmunization, saving the lives of thousands of babies.
About Us